Agent Skills
› brycewang-stanford/Awesome-Journal-Skills
› cc-study-design
cc-study-design
GitHub用于设计或审核癌症研究实验方案，确保跨体外、体内及人类肿瘤系统的正交验证。涵盖对照设置、生物/技术重复区分、样本量计算、随机化与盲法，旨在提升研究严谨性以满足Cell Press发表要求。
Trigger Scenarios
机制仅基于单一系统（如仅细胞系）
审稿人质疑体内或患者数据相关性
对照、重复或样本量逻辑不清
规划小鼠/PDX/类器官实验且不确定严谨性要素
Install
npx skills add brycewang-stanford/Awesome-Journal-Skills --skill cc-study-design -g -y
SKILL.md
Frontmatter
{
"name": "cc-study-design",
"description": "Use when designing or auditing the experimental plan for a Cancer Cell (Cell Press) study — orthogonal validation across in vitro, in vivo, and human tumor systems, with controls, replicates, power, randomization, and blinding. It plans design; it does not run statistics or write figures."
}
Experimental Design (cc-study-design)
When to trigger
- The mechanism rests on a single system (e.g., cell lines only)
- Reviewers will ask "is this true in vivo?" or "does it hold in patients?"
- Controls, replicates, or sample-size logic are unclear
- Planning mouse / PDX / organoid experiments and unsure about rigor elements
Orthogonal validation ladder
Cancer Cell expects a mechanism corroborated across independent, complementary systems. Build the strongest ladder the biology allows:
| Layer | Systems | Role |
|---|---|---|
| In vitro | Cell lines (multiple, authenticated), primary cells, co-cultures, biochemistry | Establish mechanism, gain/loss-of-function, epistasis |
| Functional genetics | CRISPR KO/KI, shRNA/siRNA with rescue, point mutants, degrons | Causality and specificity |
| In vivo | GEMM, syngeneic, xenograft, PDX, orthotopic, metastasis models | Mechanism operates in a tumor in an organism |
| 3D / ex vivo | Tumor organoids, patient-derived organoids, slice cultures, spheroids | Bridge to human, drug response |
| Human | Patient tumor samples, TMAs, scRNA-seq, public cohorts (TCGA), outcome data | Translational anchor / clinical relevance |
A Cancer Cell paper typically spans in vitro + in vivo + a human anchor. Decide early which layers carry the causal claim and which provide corroboration.
Controls (the parts reviewers attack)
- Genetic perturbation: include rescue / add-back; use ≥2 independent sgRNAs or shRNAs (or rule out off-target); non-targeting / scramble control matched to delivery.
- Pharmacology: vehicle control, dose-response, on-target genetic phenocopy, and where possible a resistant mutant or analog.
- In vivo: isotype/vehicle controls, littermate or co-housed controls for GEMMs, tumor-volume and endpoint pre-defined.
- Antibody / staining: isotype, KO/KD-validated, single-stain compensation for flow.
Replicates: biological vs technical
- Biological replicates = independent biological units (separate mice, independent cell passages/cultures, distinct patients). These define
n. - Technical replicates (duplicate wells, repeat measurements) reduce measurement noise but do not increase
n. - Report both clearly; never inflate
nwith technical replicates (seecc-statistics).
Sample size, randomization, blinding (especially animals)
- Power / sample size: justify mouse
n(effect size + variance from pilot or literature); state the basis even if informal. - Randomization: allocate animals to arms randomly (e.g., when tumors reach a set volume), not by cage convenience.
- Blinding: blind outcome assessment (tumor measurement, histology scoring, imaging quantification) wherever feasible.
- Inclusion/exclusion: pre-define humane endpoints and exclusion criteria; report all animals/samples and any exclusions.
Human-sample design
- Define cohort, inclusion/exclusion, and how samples link to outcomes.
- Power survival / association analyses; pre-specify primary comparison.
- Note IRB/consent (route to
cc-ethics-registration).
Checklist
- Mechanism validated across ≥2 orthogonal systems; causal layer identified
- In vivo evidence present (GEMM / xenograft / PDX / orthotopic) where claims require it
- Genetic perturbations include rescue and ≥2 independent reagents
- Matched controls defined for every perturbation and treatment
- Biological vs technical replicates distinguished;
n= biological units - Animal sample size justified; randomization and blinding specified
- Inclusion/exclusion criteria and humane endpoints pre-defined
- Human-sample cohort and primary comparison pre-specified
Anti-patterns
- Conclusions from a single cell line or a single system
- shRNA/CRISPR phenotype with no rescue (off-target not excluded)
- "n=3" that is three wells of one experiment (pseudo-replication)
- Mouse experiments with no randomization, no blinding, no power basis
- Therapeutic efficacy claimed without an in vivo tumor model
- Selecting samples post hoc to fit the hypothesis
Output format
【Causal claim layer】in vitro / in vivo / human
【Orthogonal systems planned】...
【Controls per perturbation】rescue + 2 reagents? vehicle/isotype?
【Replicates】biological n = ... ; technical handled separately
【Animal rigor】power basis / randomization / blinding / endpoints
【Human anchor】cohort + primary comparison
【Gaps to close before submission】...
【Next step】cc-reporting-standards (rigor reporting) or cc-statistics
Version History
- 1839142 Current 2026-07-05 12:26
